Tilray Brands, Inc., a cannabis research, cultivation, production and distribution organisation, announces its support for the opening of the German medical cannabis market and the positive paradigm shift in German drug policy.
Today’s passage of the German medical cannabis act represents a significant step forward, putting public health in the spotlight while providing patients with easier access to high-quality cannabis medicines produced in Germany.
Tilray Medical's Chief Strategy Officer and Head of International Denise Faltischek comments: "The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs."
"Facilitating access to the highest quality cannabis medicines through the new Medical Cannabis Act, produced in Germany, will help to improve patient care and provide patients with a wider range of treatment options."
Tilray Medical looks forward to working with numerous partners to utilise the production capacity at Tilray’s state of the art Neumünster site, which is one of only three cannabis cultivation facilities located in Germany, in order to ensure that patients have improved access to the highest quality cannabis medicines.
As a leader in the field of medical cannabis research and production, Tilray Medical strongly believes that these developments will have a positive impact on the health and well-being of many patients in Germany.
